Screener
ANI Pharmaceuticals ANIP Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash Flows From Operating Activities | ||
| Net income | $54,203 | $24,230 |
| Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities: | ||
| Stock-based compensation | 21,597 | 18,470 |
| Deferred taxes | (2,423) | (6,919) |
| Depreciation and amortization | 40,559 | 46,172 |
| Unrealized (gain) loss on investment in equity securities | (6,494) | 589 |
| Non-cash operating lease expense | 909 | 846 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's stock-based comp?
- ANI Pharmaceuticals (ANIP) reported stock-based comp of $11.41M in Q2 2026.
- How has ANI Pharmaceuticals's stock-based comp changed year-over-year?
- ANI Pharmaceuticals's stock-based comp increased by 18.8% year-over-year, from $9.6M to $11.41M.
- What is the long-term trend for ANI Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's stock-based comp has grown at a 37.9% compound annual growth rate (CAGR), from $10.49M to $37.93M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about ANI Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude